Shares of Supernus Pharmaceuticals, Inc. (SUPN) are up more than 7% Monday morning at $28.72.
On Aprii 2, Supernus had announced that Qelbree, the company's drug candidate, has been approved by the FDA for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age.
SUPN has been trading in the range of $16.54- $31.99 in the past 52 weeks.
For comments and feedback: editorial@rttnews.com